Aromatase Inhibitor Monotherapy to Augment Height in Boys: Does It Work and Is It Safe?
Author Information
Author(s): Mitchell E Geffner
Primary Institution: Children's Hospital Los Angeles, Keck School of Medicine of the University of Southern California
Conclusion
The efficacy of aromatase inhibitors as monotherapy for height augmentation in pubertal boys with idiopathic short stature appears limited.
Supporting Evidence
- The study found an initial increase in predicted adult height after 1 year, but this did not persist after 2 to 3 years.
- Letrozole caused greater increases in testosterone and height velocity compared to anastrozole.
- Frequent side effects included vertebral abnormalities and decreases in bone density.
Takeaway
This study looked at whether certain medications can help boys grow taller, but it found that they don't really work well over time.
Methodology
The study involved 79 pubertal males with idiopathic short stature who were randomized to receive either anastrozole or letrozole daily for up to 3 years.
Potential Biases
The absence of a control group limits the ability to establish a causal relationship between the treatments and observed outcomes.
Limitations
The study lacked a contemporaneous control group and had mixed published data regarding efficacy due to small cohort sizes and varying underlying causes of short stature.
Participant Demographics
Pubertal males with idiopathic short stature, aged over 10 years, with bone ages under 14 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website